BioAtla, Inc. (BCAB )
Currency in USD Disclaimer
Subscribe Now for Delta3 AI Alerts
Don’t miss out on top stock picks and market insights. Subscribe to Delta3 AI Alerts for real-time updates and expert analysis straight to your inbox. Stay informed and maximize your investment potential.
Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
- Symbol BCAB
- Company BioAtla, Inc.
- Price $0.69
- Changes Percentage -41.82
- Change -0.4977
- Day Low $0.67
- Day High $1.08
- Year High $4.02
- Year Low $0.67
- Market Cap $33,469,659
- Price Avg 50 EMA (D) $1.77
- Price Avg 200 EMA (D) $2.01
- Exchange NASDAQ
- Volume 6,191,423
- Average Volume 1,217,566
- Open $1.07
- Previous Close $1.19
- EPS -1.7
- PE -0.41
- Earnings Announcement 2025-03-20 12:00:00
- Shares Outstanding $48,345,600
Company brief: BIOATLA, INC. (BCAB )
- Healthcare
- Biotechnology
- Dr. Jay M. Short Ph.D.
- https://www.bioatla.com
- US
- N/A
- 12-16-2020
- US09077B1044
BioAtla, Inc., a clinical stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and ovarian cancer. It also develops BA3021, a CAB ADC for multiple solid tumor types, including NSCLC, melanoma, and ovarian cancer; and BA3071, which is a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody for renal cell carcinoma, NSCLC, small cell lung cancer, hepatocellular carcinoma, melanoma, bladder cancer, gastric cancer, and cervical cancer. BioAtla, Inc. was founded in 2007 and is based in San Diego, California.
BCAB Corporation News
BioAtla, Inc. Announces Registered Direct Offering to Advance Two Mid-Stage Clinical Programs to Key Inflection Points
globenewswire.com -- SAN DIEGO, Dec. 20, 2024 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company (“BioAtla” or the “Company”) focused on the development of Conditionall...